drugset
drugset / Trial / NCT03000309

Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

NCT03000309 ↗

Phase 4 Completed 20 enrolled Derm Research, PLLC Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.

Timeline

Start
2016-12-29
Primary completion
2018-04
Completion
2018-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg —

Indications

psoriasis